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 Calculating something as simple as the prevalence ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW ふHDぶ is problematic and 
contentious. 
 Multiple sources are available to ascertain HD cases in a given population. 
 Populations that employed diagnostic testing of HD have increased their ascertained prevalence 
measures over the last two decades.  
 The estimated prevalence of HD in North America, North Western Europe and Australia ranges from 
5.96 to 13.7 cases per 100 000 population.  
 The ascertained prevalence of HD in Asia is much lower than Western populations.  
 Using multiple sources for ascertainment of HD cases, although time-consuming, is more likely to 





The ascertained prevalence of H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW ふHD) increased significantly following the provision of 
diagnostic testing. A systematic review was conducted to estimate the prevalence of HD in the post-diagnostic 
testing era. 22 studies with original data pertaining to the prevalence of HD (1993-2015) were included and 
analysed. A global meta-analysis was not performed due to heterogeneity in study methods and geographical 
variation. The prevalence of HD is significantly lower in Asian populations compared to Western Europe, North 
America and Australia. The global variation in HD prevalence is partly explained by the average CAG repeat 
lengths and frequency of different HTT gene haplotypes in the general population. Understanding the 









H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW ふHDぶ ｷゲ ; slowly progressive autosomal dominant neurodegenerative disorder 
characterised by motor abnormalities, cognitive impairment and psychiatric disturbances [1]. The disease is 
caused by an expanded CAG triplet repeat in the HTT gene which encodes an abnormal polyglutamine 
expansion in the huntingtin protein [2].  
 
HD was classically a clinical diagnosis made in the context of a positive family history of the condition. After the 
identification of the underlying genetic mutation in 1993 [2], diagnostic testing became widely available. This 
enabled clinicians to make a confident diagnosis of individuals with typical neurological features but without a 
known family history of the condition; this group may represent up to 10% of new HD cases [3]. As a 
consequence, the ascertainment of HD in populations has increased and the measured prevalence of HD in 
several populations is substantially higher in the post-diagnostic testing era [4に6]. Studies performed prior to 
1993 may therefore underestimate the true prevalence of HD.  
 
The management of HD requires the co-ordination of professionals from multiple domains including 
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neurologists, psychiatrists, psychologists, specialist nurses, physiotherapists, occupational therapists, social 
services and carer services. In order to allocate the optimal and appropriate amount of scarce resources, an 
accurate calculation of the scope of disease burden on the population is imperative. If previous estimates of 
prevalence underestimate the true prevalence, the current provision of health and social care services 
allocated to individuals with HD may be underequipped.  
 
The second issue that arises from uncertain prevalence measures is that healthcare services are unable to 
identify the number of individuals at-risk of developing HD. The ratio of symptomatic individuals (prevalence) 
to individuals at 50% risk of developing HD has been described, on theoretical grounds, as being 1:5 [7] and 
approximately 1:4.2 in empirical studies [8,9]. At present, identifying these individuals is important to be able 
to offer predictive testing, genetic counselling, emotional support and recruitment for clinical research. In the 
future, characterising and quantifying this population is significant as future disease-modifying therapies may 
be targeted at gene positive individuals in the pre-symptomatic period of HD.   
 
AIMS 
The present study will attempt to:  
1. Identify the published measurements of HD prevalence made in the era of diagnostic testing.  
2. Reconcile the geographical variation in HD prevalence explaining the factors that determine variation 




A systematic literature search was conducted using a predetermined protocol. Two computer-stored 
databases, MEDLINE (1993-2015) and EMBASE (Excerpta Medical Database; 1993-2015), were searched for 
studies investigating the prevalence ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW ｷﾐ ; SWaｷﾐWS ヮﾗヮ┌ﾉ;デｷﾗﾐく TｴW ゲW;ヴIｴ ゲデヴ;デWｪ┞ ┘;ゲ 
developed after consultation with a research librarian and is detailed in Appendix 1.  
 
Further studies were identified from the following sources 
1. Searching within references of relevant articles.  
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2. Searching for articles that cited the studies identified using the search strategy.  
3. Information from articles on the uptake of predictive testing  
4. Specialist te┝デHﾗﾗﾆゲ ﾗﾐ H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW   
5. Web searches. 
6. Online databases [10,11]  
 
 
Selection of Studies 
All studies identified by the search strategy were screened by one reviewer (S.S.B.) who excluded those that 
were irrelevant. The abstracts of the remaining studies were screened by one reviewer (S.S.B.) who excluded 
ゲデ┌SｷWゲ ┘ｴｷIｴ ┘WヴW ﾐﾗデ ﾗHゲWヴ┗;デｷﾗﾐ;ﾉ ﾗヴ SｷS ﾐﾗデ ｷﾐ┗Wゲデｷｪ;デW デｴW WヮｷSWﾏｷﾗﾉﾗｪ┞ ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲWく F┌ﾉﾉ 
texts of all the remaining studies and assessed by two independent reviewers (S.S.B. and O.W.J.Q).  
 
 
Inclusion/Exclusion Criteria  
Articles were included based on the criteria established in Table 1. Studies performed prior to 1993 were 
excluded for two major reasons. Firstly, as diagnostic genetic testing became available in 1993, studies before 
this relied solely on a clinical diagnosis of HD and, as such, had the possibility of incomplete ascertainment of 
HD cases. Secondly, as discussed in greater detail in the discussion, there is a suggestion that the true 
prevalence of HD may be increasing as the life expectancy in the general population rises [4], the most current 
studies were felt to be of most relevance. In several cases, HD prevalence measures on populations made 
before 1993 had been repeated and updated; it is these recent studies with higher ascertainment that were 
included in the present analysis.  
  
The measurement of the prevalence of HD in a population is typically performed through a cross-sectional, 
observational study. In some cases, where a registry for HD was established, the prevalence is established by 
means of a cohort study. Our qualification of observational studies is important as there are several studies 
published in the literature which estimate the prevalence of HD in different populations by using 
computational models based on the mean CAG repeat length in the general population and the common HTT 
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gene haplotypes rather than on observed data on the number of individuals with a diagnosis of HD. 
 
Data Extraction 
For each study, data extracted included the region studied, population size, prevalence date, sources of case 
ascertainment, di;ｪﾐﾗゲデｷI IヴｷデWヴｷ;が ﾐ┌ﾏHWヴ ﾗa I;ゲWゲ ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲWが prevalence per 100 000 
population and methodological limitations of the study. 95% confidence intervals were calculated for each 
prevalence estimate using the Agresti Coull method [12].  
  
Data Analysis 
Due to the heterogeneity between studies with respect to their methods of identifying, diagnosing and 
ヴWIﾗヴSｷﾐｪ H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW I;ゲWゲが ｷデ was felt to be inappropriate to combine all the studies and perform a 
meta-analysis to provide pooling statistics. Where pooled estimates were reported, a DerSimonian and Laird 
random effects model for the logit transformed prevalences was assumed. [13]. All calculation was performed 
using the meta package in R 3.2.3.  
RESULTS 
Figure 1 shows the selection of cases for the systematic review. 3397 studies were identified through 
MEDLINE, EMBASE, web searches, citation searches, searches within references from previous review articles 
and selected studies, textbooks and from prior knowledge. Titles were screened for 2030 non-duplicate 
studies and 217 abstracts were screened. 175 abstracts were excluded as they were either duplicates or did 
not meet the inclusion criteria. 41 full text articles and 8 conference abstracts were assessed in detail for 
eligibility with 19 excluded. In addition, twelve review articles on HD epidemiology were identified but 
searches through the references did not yield any additional studies [14に25].  
 
Of the excluded studies: five estimated the HD prevalence before 1993 [26に30], four studied specific 
subgroups that were not representative of the whole population [31に34] , four were not population-based 
observational studies and estimated the prevalence indirectly [35に38], two studied small geographical clusters 
of high prevalence [39,40], two had insufficient information regarding case ascertainment [41,42] ,one did not 
differentiate between symptomatic individuals and asymptomatic mutation positive individuals [43] and one 
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was not written in English [44]. 
 
Twenty-two studies examining HD prevalence (eighteen original articles and four conference abstracts) were 
included in the qualitative analysis. Fifteen studies were conducted in European populations, one in North 
America, two in Australia and four in Asia. The hypothetical global mean prevalence based on pooling all the 
data from the studies included in the present systematic review in a meta-analysis would be 5.5 per 100,000; 
However, the interpretation and application this figure as an average global prevalence of HD would be 
inappropriate  due to the heterogeneity between the included studies. 
 
Table 2 details the results of the systematic review. It contains the ascertained prevalence of HD in different 
populations from four continents. Figure 2 shows a funnel plot of prevalence (per 100,000 population) against 
population size. The hypothetical global mean prevalence  is shown as a dashed vertical line, as are 95% 
control limits. Significant overdispersion is evident, suggesting that variation in prevalence estimates is due to 
causes other than simple sampling variability. There is no evidence of a relationship between prevalence and 
population size, though regional differences are clearly seen. 
 
Figure 3 shows Forest Plots representing studies of HD prevalence from four continents. Figure 4 illustrates the 
ascertained prevalence of HD in different studies geographically. 
 
DISCUSSION 
TｴW ヮヴWゲWﾐデ ゲデ┌S┞ ｷゲ デｴW ﾏﾗゲデ IﾗﾏヮヴWｴWﾐゲｷ┗W ゲ┞ゲデWﾏ;デｷI ヴW┗ｷW┘ ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW (HD) epidemiology 
conducted in the post-diagnostic testing era. It identifies prevalence estimates from populations in four 
continents and indicates marked variation in the prevalence of HD. It indicates that the ascertained prevalence 
of HD has increased significantly following the advent of diagnostic testing and details the higher prevalence of 
HD in European, North American and Australian populations relative to Asian populations.  
 
The recorded prevalence of HD in several individual populations has increased after the introduction of genetic 
testing [4に6,9,45,46]. The study performed in Finland showed a four-fold increase in the prevalence of HD 
following the introduction of genetic testing [6]. This may partly be explained by the ability to diagnose 
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individuals with a negative family history (new mutations, historical misdiagnosis in family members, non-
penetrance, non-paternity) through genetic testing [1]. Additionally, as the life expectancy in the general 
population increases, individuals may present with HD in later life; this may be particularly relevant individuals 
with reduced penetrance alleles who develop symptoms in later life [4,47]. Other factors that may contribute 
towards the increase in recorded prevalence of HD over time include the use of diagnostic testing earlier in the 
course of the illness e.g. with early cognitive or behavioural symptoms with subtle motor symptoms in the 
context of a positive family history. In populations where the prevalence of HD has previously been low, 
increased clinician familiarity with the disease entity may contribute to the increase in recorded prevalence.  
 
In the UK, two recent studies used primary care research databases to determine the current prevalence of HD 
which resulted in two strikingly different estimates of 5.96 [48] and 12.3 [5] per 100,000 of the population. The 
larger estimate, however, describes the prevalence in the over 20 population where HD is far more common. 
When the findings of Evans et al were combined with an additional publication by their group describing the 
prevalence of HD in the under-21 population [49] , the HD prevalence in the UK in 2010 was estimated to be 
9.28 per 100 000 population. The residual difference between the two primary care research databases 
remains unaccounted for.  
 
There is significant global variation in the prevalence of HD. A substantial proportion of the measured 
differences in HD prevalence is secondary to variation in the true prevalence of HD i.e. geographical 
differences that would persist even if there was complete ascertainment of every case of HD.  Nevertheless, 
this variation may, in part, be explained by factors that affect the complete ascertainment of individuals with 
HD. The possible reasons for differences in true and ascertained prevalence of HD are summarised in Table 3.  
 
A major biological determinant of differences in the true prevalence of HD between populations is the mean 
CAG repeat length in the general population. Populations with a higher prevalence of HD e.g. European 
populations have been shown to have a higher mean CAG repeat length in the HTT gene in the non-affected l 
population when compared to populations with a lower prevalence of HD e.g. Japan and China [50,51]. There 
is thought to be a causal relationship between the two factors as populations with a greater proportion of 
individuals with CAG repeat lengths in the high-normal range serve as a pool of potential new mutations with 
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expansion of the CAG repeat length in subsequent generations, first into the intermediate allele range (27-35 
repeats) and then into the affected range (д ンヶ ヴWヮW;デゲ) [47]. Another significant biological determinant of 
variation in the true prevalence of HD is the haplotype of the HTT gene. Warby et al (2009) determined that, in 
a European population, CAG expansion in the HTT gene occurs with significantly increased frequency on two 
haplotypes, A1 and A2, compared to haplogroups B and C [52]. In East Asian individuals, however CAG 
expansions are associated most with haplotype C [53]. Warby et al (2011) further demonstrated that these 
high risk haplotypes, A1 and A2, are present in 20% of the individuals from the general European population 
(with < 27 CAG repeats) but were absent in a sample of the general population of East Asia [53]. The proposed 
explanation of these findings is that  the mutation rate of the CAG expansion in the HTT gene is more likely to 
occur on haplotypes A1 and A2 because other cis elements make these CAG repeat length on these 
chromosomes more unstable. As these haplotypes are more common in European populations compared to 
East Asian populations, this may explain the markedly higher prevalence of HD in the former. Thirdly, in 
geographically isolated populations such as Iceland and Malta, the founder effect may explain some of the 
variation seen. [54,55].  
 
As mentioned, variation in HD prevalence may be explained by factors that affect the ascertainment of 
individual cases of HD when healthcare researchers attempt to determine prevalence measures. There are 
several data sources utilised by healthcare workers in order to identify individuals with HD; each of these these 
has its own advantages, disadvantages, sensitivity, specificity and error rate. For instance, a study which takes 
data from a centralised testing centre which runs a regional HD service led by a small number of clinicians who 
are intimately involved in the local HD community and who actively characterise HD pedigrees in order to 
determine accurately the prevalence [4,56] is more likely to have a higher prevalence figure than a data source 
which relies on coding such as hospital discharge summaries.  
 
Errors in the measured prevalence of HD prevalence can arise through multiple routes. For instance, if 
individual cases are not cross-referenced with death notifications, deceased individuals may incorrectly be 
included in point prevalence measures; in essence, the reported prevalence may in fact be the cumulative 
incidence over the study period. In addition, the onset of HD is insidious; therefore, ideally, a prevalence date 
needs to be a little earlier than the study date to allow for the fact that some individuals in the study 
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population will be symptomatic but undiagnosed at the time of the study but were affected at the time of the 
earlier prevalence date.  Individuals who have been identified as having an abnormal CAG expansion through a 
predictive testing but who are currently presymptomatic should not be included within prevalence measures 
of HD. However, in studies where data on individuals with HD is extracted from the relevant administrative 
code on a large databases e.g. primary care records and national insurance databases, there is a possibility 
that some presymptomatic individuals may have been incorrectly coded as having a diagnosis of HD. This can 
be overcome by healthcare researchers accessing the clinical records of all cases of HD identified in large 
datasets to confirm the diagnosis, however, this requires additional ethical approval and a greater number of 
resources. There are a number of conditions which may be incorrectly diagnosed as HD but are not caused by 
an abnormal CAG expansion in the HTT ｪWﾐWく TｴWゲW IﾗﾐSｷデｷﾗﾐゲが デWヴﾏWS けHD phenocopy syndromesげ I;ﾐ IﾉW;ヴﾉ┞ 
be ruled out by the use of diagnostic genetic testing, however, in individuals with a purely clinical diagnosis of 
HD, upto 1% of cases actually represent HD phenocopy syndromes [57]. Further, poor response rates and 
incomplete information from clinician surveys, family surveys and family pedigrees can lead to an 
underascertainment of cases.  
 
 The use of multiple sources to identify individuals with HD has been instrumental in improving the 
ascertainment of HD prevalence. In British Columbia, the use of several sources for identifying individuals with 
HD yielded the highest prevalence estimate of HD in a Western population [4]. The issues that arise with 
multiple source ascertainment include its time-consuming and costly nature, the possibility of including the 
same individual twice or more in prevalence ﾏW;ゲ┌ヴWゲ ふけSﾗ┌HﾉW-Iﾗ┌ﾐデｷﾐｪげぶ and the practical difficulties in 
carrying this out in a large population.  
 
A key limitation of the current study is the absence of studies that were not conducted in the English language. 
The authors are aware of one such study in the San-in area of Japan [44]; however, the estimated prevalence 





The present study demonstrates an increase in the ascertained prevalence ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ disease (HD) in 
several populations and indicates marked global geographical variation in the prevalence of the disease which 
is likely explained by the mean CAG repeat length in the unaffected population, HTT haplotypes and the 
variable use of multiple sources of ascertainment to determine the prevalence of HD. Optimising the 
ascertainment of HD cases in a given population requires the recording of cases from multiple sources with 
safeguards to prevent double-counting of individuals in the reported estimates.  
 
FUTURE PERSPECTIVE  
Five studies on HD prevalence were published in 2015 suggesting there is continued interest in the 
epidemiology of HD [6,39,46,59,60]. Accurately characterising the prevalence of the condition is necessary to 
allocate the optimal amount of resources for health and social care resource provision, research funding and 
psychological counselling.  
 
The aim of the future treatment for HD is to alter the natural history of the disease. Ideally, treatment should 
start in the pre-symptomatic phase. The ratio of 50% at-risk individuals to symptomatic individuals is either 
4.2:1 or 5:1 [7,8]. There are currently several active clinical trials for drug therapy in HD; if even a single study 
shows a neuroprotective effect, it is likely that the demand for predictive testing services will markedly 
increase. Therefore, accurately determining the prevalence of HD, and thereby the at-risk population size, may 
become increasingly important in the future.  
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APPENDIX 1 
Search strategy of electronic databases (EMBASE and MEDLINE).   
 
Search History 
 1. EMBASE; (Huntington* AND prevalence).ti,ab [Limit to: Publication Year 1993-2015]; 292 results. 
2. EMBASE; (Huntington* AND population).ti,ab [Limit to: Publication Year 1993-2015]; 718 results. 
3. EMBASE; (Huntington* AND incidence).ti,ab [Limit to: Publication Year 1993-2015]; 151 results. 
4. EMBASE; (Huntington* AND epidemiology).ti,ab [Limit to: Publication Year 1993-2015]; 54 results. 
5. EMBASE; 1 OR 2 OR 3 OR 4 [Limit to: Publication Year 1993-2015]; 1022 results. 
6. Medline; exp HUNTINGTON DISEASE/ [Limit to: Publication Year 1993-2015]; 6845 results. 
7. Medline; (prevalence OR population OR epidemiology OR incidence).ti,ab [Limit to: Publication Year 1993-
2015]; 1435583 results. 
8. Medline; 6 AND 7 [Limit to: Publication Year 1993-2015]; 409 results. 
9. Medline; (Huntington* AND prevalence).ti,ab [Limit to: Publication Year 1993-2015]; 177 results. 
10. Medline; (Huntington* AND population).ti,ab [Limit to: Publication Year 1993-2015]; 455 results. 
11. Medline; (Huntington* AND epidemiology).ti,ab [Limit to: Publication Year 1993-2015]; 32 results. 
12. Medline; (Huntington* AND incidence).ti,ab [Limit to: Publication Year 1993-2015]; 93 results. 
13. Medline; 9 OR 10 OR 11 OR 12 [Limit to: Publication Year 1993-2015]; 772 results. 
14. EMBASE; exp HUNTINGTON CHOREA/; 19324 results. 
15. EMBASE; (prevalence OR population OR epidemiology OR incidence).ti,ab; 2278710 results. 
16. EMBASE; 14 AND 15; 1194 results. 
17. EMBASE; 5 OR 16 [Limit to: Publication Year 1993-2015]; 1199 results. 
18. Medline; 8 OR 13 [Limit to: Publication Year 1993-2015]; 820 results. 
 





































Figure 1: Flow chart of systematic review procedure for identifying and selecting studies for reporting the 
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Figure 2 -  Funnel plot of population size against HD prevalence using data from studies meeting the inclusion 












































Figure 3 に Forest plots of studies of H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW prevalence by continent.  






Figure 4 -  Ascertained Prevalence ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ DｷゲW;ゲW ｷﾐ DｷaaWヴWﾐデ Pﾗヮ┌ﾉ;デｷﾗﾐゲ ふヱΓΓン-2015). Bubble diameter proportional to prevalence per 100 000 population.  





Table 1 - Study Design and Selection Criteria 
Study Design   
Selection Criteria for Studies  Population-based observational studies 
 Defined population  
 AゲIWヴデ;ｷﾐﾏWﾐデ ﾗa ゲ┞ﾏヮデﾗﾏ;デｷI I;ゲWゲ  ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲW 
 Study conducted from 1993 onwards 
  
Population IﾐSｷ┗ｷS┌;ﾉゲ ┘ｷデｴ ; Sｷ;ｪﾐﾗゲｷゲ ﾗa H┌ﾐデｷﾐｪデﾗﾐげゲ SｷゲW;ゲWく 
  













Sources of Case Ascertainment Diagnostic Criteria Population Size 





















HR, CR, Lab, Family Federation of 






Clinical phenotype plus either a family history of 
HD, a family history or motor symptoms 
suggesting HD or a positive DNA analysis (CAG 
repeat length ≥ 37) 
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Northern Ireland 2001 
Prospective: CTC, HDR 
Clinical phenotype with a positive DNA analysis 
(CAG repeat length ≥ 36) 
1 698 113 
(calculated) 180 10.6 (9.16 – 12.27) 
Morrison et al (2011) 
[9] 
United Kingdom 2008 
PCD (THIN) Administrative Read code 2 964 386 Unspecified 5.97 (5.15 – 6.92) 
Sackley et al (2011) 
[48] 
United Kingdom 2010 
PCD (GPRD) Administrative Read code 4 683 669 435 9.29 (8.45 – 10.20) 
Douglas et al (2013) 






Clinical phenotype or clinical phenotype with 




HDR (Leiden Roster) Unspecified 15 930 000 Unspecified 6.50 (6.11 - 6.91) 
Maat-Kievit et al 
(2000) [62] 




Unspecified (likely used death 











2.48 (1.73 – 3.53) 
 
 
Reverberi et al (2014) 
[63] 
 
Italy (Molise) 2013 
HR, CR, HDA RDR, FS 
Clinical phenotype or clinical phenotype with 






























Clinical phenotype or clinical phenotype with a 

































Spain (Navarra) 2014 
HR, CR, PCD 
Clinical phenotype plus a family history of HD or 
a positive DNA analysis (CAG repeat length 
unstated) 
660 000 
(calculated) 33 5.00 (3.54 – 7.05) 
Vincente et al (2014) 
[65] 
Slovenia 2006 
HR, CR, HDR, CTC, HDA 
Clinical phenotype with a positive DNA analysis 
(CAG repeat length ≥ 37). 2 011 614 104 5.17 (4.26 - 6.27) 





National Genetic Register Unspecified 1 250 000 152 3.70 (3.15 – 4.34) 
Maghzhanov et al 
(2012) [67] 
        NORTH AMERICA 
Canada (British 
Columbia) 2012 
HR, CR, Lab, CS, FS, NH, PCR, 
HDA 
Clinical phenotype or clinical phenotype with a 
positive DNA analysis (CAG repeat length ≥ 36) 4 609 659 633 13.7 (12.7-14.8) 
Fisher and Hayden 
(2014) [4] 
   
 
 







HR, CS, HAD, FS 
 
 
Clinical phenotype plus a family history of HD or 
a positive DNA analysis (CAG repeat length 
unstated) 









McCusker et al (2000) 
[3] 
 
Australia (Victoria) 1999 Lab, CTC Unspecified 4 736 000 382 8.07 (7.30 – 8.92) 
Tassicker et al (2009) 
[8] 
        ASIA 





Clinical phenotype with a positive DNA analysis 
(CAG repeat length unstated) and atrophy of the 
caudate nucleus on CT/MRI 




0.65 (0.32 – 1.25) 
 





Japan Intractable Disease 
Information Center, Department of 
the Specific Disease Control, 
Japanese Ministry of Health, Labor 
and Welfare. Unspecified 




0.70 (0.66 – 0.75) 
 
 










HR, HDR, RDR 
 
 
Administrative codes on NHI database or clinical 
phenotype with a positive DNA analysis 






0.41 (0.35 – 0.47) 
 
 
Kim et al (2015) [60] 
 




Legend for Table 2   
 
HR Hospital Records and Hospital Discharge Registers 
CR Clinic Records 
CS Clinician Surveys  
Lab Genetic Testing Laboratories 
CTC Centralised Testing Centre 
HDR H┌ﾐデｷﾐｪデﾗﾐげゲ DｷゲW;ゲW ‘Wｪｷゲデヴ┞ 
RDR Rare Disease Registry 
PCD Primary Care Database 
NHI National Health Insurance Database 
HDA H┌ﾐデｷﾐｪデﾗﾐげゲ DｷゲW;ゲW AゲゲﾗIｷ;デｷﾗﾐ 
FS Family Surveys and Family Pedigrees 
NH Nursing Homes 
VA Veteran Affairs 
SS Social Services 
DC Death Certificates 
THIN  The Health Improvement Network 
 











Table 3 - Factors that may explain the geographical variation in HD prevalence. 
Factors that may explain the geographical variation in HD prevalence 
Differences in the 
true prevalence  
Average length of CAG repeat in the unaffected population which correlates to the 
new mutation rate [50,51] 
Frequency of A1 and A2 HTT haplotypes in the unaffected population. [53] 
The founder effect in small, geographically isolated populations. [54,55] 
Life expectancy in the general population. [47] 
 
Differences in the 
ascertainment of 
HD cases.  
Sensitivity and specificity of the data sources used for case ascertainment.  
The use of single or multiple sources for case ascertainment.  
Ease of accessing healthcare services in order to diagnose HD. 
Clinician familiarity with HD as a disease entity. 
The presence of large private or informal healthcare sector leads to an 
underascertainment of HD cases in national registers.  
Different incentives to hide a diagnosis of HD depending on local social stigma, real or 
perceived employment discrimination or insurance-based healthcare provision.  
 
 
 
 
 
